Tests two drugs given with clot removal for acute stroke

Who can take part

• Clinical Inclusion Criteria:; Age between 18-80 years(including the critical value); Ischemic stroke with a National Institutes of Health Stroke Scale (NIHSS) score ranging from 6-20; Time from last known to be well to randomization within 24h; Pre-stroke Modified Rankin Scale scoring 0-1; With indications of reperfusion therapy (including intravenous thrombolysis and endovascular thrombectomy); Informed consent signed by patients or their legal relatives; CT angiography (CTA) confirmed large vessel occlusion of anterior circulation; Alberta Stroke Program Early Computed Tomography Score (ASPECT) score of 6-10; initial infarct volume on CT perfusion (CTP) lesser than 70ml; a ratio of hypoperfused volume to infarcted volume greater than 1.8; absolute mismatch volume greater than 15 ml according to DEFUSE-3 trial

Who cannot take part

• Image exclusion criteria:; computed tomographic angiography（CTA）/magnetic resonance angiography（MRA）/digital substraction angiography（DSA） shows excessive vascular curvature, which may hinder delivery of interventional devices; Cerebrovascular inflammation is suspected based on medical history and CTA/MRA/DSA; Aortic dissection is suspected based on medical history and CTA/MRA/DSA; CTA/MRA/DSA confirmed multi-vascular regional occlusion (such as bilateral anterior circulation or anterior/posterior circulation, extracranial carotid artery with intracranial tandem lesions), or clinical evidence of bilateral or multi-regional infarction; CTA/MRA/DSA confirms moyamoya disease or moyamoya syndrome; CT/MRI confirmed a significant midline shift effect; CT/MRI confirms the presence of intracranial tumors (except cerebellar meningioma) CT/MRI confirmed intracranial hemorrhage
• Clinical Exclusion Criteria:; Clinical findings suggest intracranial parenchymal hemorrhage or subarachnoid hemorrhage; Accompanied by epilepsy; Accompanied by coma or mental disorders, may interfere with neurological function assessment; History of premorbid phenothiazine allergy or contraindication; History of allergy to iodine contrast medium or anaphylactic shock; Baseline blood glucose <50mg/dL (2.78mmol) or >400mg/dL (22.20mmol); Acceptable fingertip blood glucose results; Baseline platelet <50×109 /L; Recent (i.e. within 30 days prior to randomization) history of gastrointestinal or other clinically significant bleeding; Active bleeding, abnormal clotting factors, or bleeding tendency (INR≥3 or PT≥3×ULN on anticoagulants; If the investigator believes that the subject does not have coagulation dysfunction, it is not necessary to wait for the results of the coagulation test before deciding whether to enroll.); The stroke is accompanied by fever, or there is an active infection requiring systemic treatment (such as active tuberculosis, etc.); Expected survival less than 90 days (According to the Chinese Guidelines for Early Endovascular Interventional Diagnosis and Treatment of Acute Ischemic Stroke 2022, expected survival less than 90 days is a contraindication for endovascular therapy); A history of severe cardiovascular disease, including but not limited to: uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >105 mmHg after standard treatment), hypotension (systolic blood pressure ≤100 mmHg after standard treatment), or pulmonary hypertension; Had unstable angina pectoris, myocardial infarction, or bypass or stent surgery within 6 months before randomization; New York Heart Association (NYHA) grade 3-4 history of chronic heart failure; Clinically significant valvular disease; Severe arrhythmias requiring treatment (except atrial fibrillation and paroxysmal supraventricular tachycardia), including QT interval ≥450ms for men and ≥470ms for women; accompanied by chronic obstructive pulmonary disease（COPD）, tuberculosis, pneumonia, pneumothorax, atelectasis, pulmonary fibrosis, bronchopulmonary dysplasia, pleural effusion, acute respiratory distress syndrome, respiratory irregularity and other lung diseases; Severe hepatic and renal insufficiency, including but not limited to: cirrhosis, hepatic encephalopathy, ascites, renal failure or uremia (Ccr<25ml/min), hepatorenal syndrome, etc; Pregnancy or lactating women; Participation in other clinical trials and have used an investigational drug or medical device; Patients that may not be able to complete the study for other reasons or who the investigator believes should not be included